COVID-19 Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "COVID-19 Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the COVID-19 Pipeline @ https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the COVID-19 Pipeline Report
• On July 09, 2026- Pfizer initiated a phase 3 study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.
• DelveInsight's COVID-19 Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies such as Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• Promising COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Get insights into COVID-19 clinical trials, emerging therapies, and leading companies with DelveInsight @ https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The COVID-19 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The COVID-19 Pipeline Report also highlights the unmet needs with respect to the COVID-19.

COVID-19 Overview
COVID-19 is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus. COVID-19 has had a catastrophic effect on the world, resulting in more than 6 million deaths worldwide. Like other RNA viruses, SARS-CoV adapts with genetic evolution and developing mutations. This results in mutant variants that may have different characteristics than their ancestral strains. The symptoms of COVID-19, caused by SARS-CoV-2, vary widely in severity, ranging from asymptomatic infection to severe respiratory illness. The most common symptoms include fever, dry cough, fatigue, and shortness of breath, often accompanied by sore throat, headache, and muscle aches. Many individuals also experience loss of taste or smell, which became a distinguishing feature of the disease. In some cases, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur. Severe cases can progress to pneumonia, chest pain, confusion, and difficulty breathing, potentially leading to acute respiratory distress and multi-organ complications.

COVID-19 Emerging Drugs Profile
• VYD-2311: Invivyd, Inc.
VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd's proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.

• Ibuzatrelvir: Pfizer
Ibuzatrelvir (PF-07817883) is an investigational, second-generation oral SARS-CoV-2 main protease inhibitor developed by Pfizer to treat COVID-19. It acts as a single agent without requiring ritonavir boosting, offering a potential advantage in reducing drug-drug interactions, and has shown significant viral reduction in Phase 2 trials. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.

• N-803: ImmunityBio, Inc.
N-803 is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor's low pH environment. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

• ENTVAX002: Entos Pharmaceuticals Inc.
ENTVAX002 (also known as Covigenix VAX-002) is an investigational, next-generation COVID-19 booster vaccine developed by Entos Pharmaceuticals in partnership with Aegis Life. It is a plasmid DNA (pDNA) vaccine specifically engineered to combat emerging SARS-CoV-2 Omicron variants, utilizing the company's proprietary Fusogenix proteo-lipid vehicle (PLV) platform for delivery. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

• ALG-097558: Aligos Therapeutics
ALG-097558 is a potent ritonavir-free pan-coronavirus protease inhibitor (PI). In preclinical studies, ALG‐097558 has been shown to be at least 6-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants. It has demonstrated broad pan-coronavirus activity, including against SARS and MERS. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.

• RBM001: Rock BioMedical, Inc.
RBM001 is a low-sugar, broad-spectrum COVID-19 protein vaccine developed by Rock BioMedical, a Taiwan-based biotech company. The vaccine is designed to address rapidly mutating viruses by removing glycan shields from the spike protein, exposing highly conserved, less-mutable areas to the immune system, thus providing wider protection against various strains. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

• MDX2301: OPKO Health, Inc.
MDX2301 is a multispecific antibody therapy for the prevention of COVID-19 designed to neutralize diverse SARS-CoV-2 variants. The ModeX multispecific antibody format enables the rational combination of multiple binding sites in a single antibody, aiming to broaden coverage against current and future viral variants while enabling potent neutralization and the potential for enhanced therapeutic efficacy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

• PA-001: PeptiDream Inc.
PA-001, a peptide-based inhibitor targeting the S2 domain of the SARS-CoV-2 spike protein, a protein essential for coronavirus entry into human cells. The S2 region is highly conserved across variants and subvariants, and PA-001 demonstrated potent activity against all major variants from Wuhan to Omicron BA.5. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.

Explore groundbreaking therapies and clinical trials in the COVID-19 Pipeline @ https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The COVID-19 Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of COVID-19 with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for COVID-19 Treatment.
• COVID-19 Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• COVID-19 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the COVID-19 market

COVID-19 Companies
Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

COVID-19 Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new COVID-19 drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the COVID-19 Pipeline Report
• Coverage- Global
• COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth COVID-19 Pipeline report today! @ https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. DAS181: Ansun Pharm
8. Drug profiles in the detailed report.....
9. Mid Stage Products (Phase II)
10. MP1032: MetrioPharm
11. Drug profiles in the detailed report.....
12. Early Stage Products (Phase I/II)
13. GLS-5310: GeneOne Life Science
14. Drug profiles in the detailed report.....
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.